Hoffmann-La Roche: Head and Neck Neoplasms trials
The registry lists 10 Head and Neck Neoplasms studies with Hoffmann-La Roche as lead sponsor. 0 are open to participants now and 4 have results posted.
Phase 1 5Phase 2 4Phase 3 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid TumorsTerminatedNCT04644315Phase 2Results posted
- A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT04222972Phase 3Results posted
- Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid TumorsCompletedNCT03037385Phase 1/2Results posted
- A Study of Erlotinib (Tarceva) in Participants With Resected Head and Neck Squamous Cell CancerTerminatedNCT00412217Phase 3Results posted
- A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic TumorsCompletedNCT03289962Phase 1
- A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)CompletedNCT02627274Phase 1
- Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)CompletedNCT02568267Phase 2
- A Study of MEHD7945A in Combination With Cisplatin and 5-Fluorouracil (5-FU) or Paclitaxel and Carboplatin in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)CompletedNCT01911598Phase 1
- A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And NeckCompletedNCT01577173Phase 2
- A Study of Pharmacodynamics of RO5083945 in Patients With Head and Neck Squamous Cell CarcinomaCompletedNCT01046266Phase 1